Drugs / BCX10013
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06100900 | Oct 2023 → Dec 2024 | paroxysmal nocturnal hemoglobinuria | BioCryst Pharmaceuticals | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2023-11-03 | BioCryst Pharmaceuticals | Results BioCryst R&D Day Highlights New Diversified Pipeline of First-in-Class/Best-in-Class Therapies with Five Programs Expected in Clinical Development in Next 24 Months biocryst.com ↗
At the R&D Day, the company plans to present data from the recently completed 160 mg cohort of its multiple ascending dose healthy volunteer trial which highlights the strength and duration of alternative pathway suppression achieved at this dose level, supporting once-daily clinical dosing. |
| 2023-01-09 | BioCryst Pharmaceuticals | Results BioCryst Reports Initial Clinical Data with Oral Factor D Inhibitor BCX10013 Supporting Development as a Once-daily Treatment for Complement-mediated Diseases biocryst.com ↗
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that initial data from ongoing phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) trials in healthy volunteers show rapid, sustained and >97 percent suppression of the alternative pathway (AP) of the complement system 24 hours following a single 110 mg dose. |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-11-03 | BioCryst Pharmaceuticals | BioCryst R&D Day Highlights New Diversified Pipeline of First-in-Class/Best-in-Class Therapies with Five Programs Expected in Clinical Development in Next 24 Months biocryst.com ↗ |
| 2023-10-26 | BioCryst Pharmaceuticals | BioCryst Begins Enrollment in Proof-of-Concept Trial to Confirm Safe, Effective, Once-daily Dose of Oral Factor D Inhibitor, BCX10013 biocryst.com ↗ |
| 2023-01-09 | BioCryst Pharmaceuticals | BioCryst Reports Initial Clinical Data with Oral Factor D Inhibitor BCX10013 Supporting Development as a Once-daily Treatment for Complement-mediated Diseases biocryst.com ↗ |
| 2022-12-15 | BioCryst Pharmaceuticals | BioCryst Discontinues Development of BCX9930 and Shifts Focus to Potential Once-daily, Oral Factor D Inhibitor, BCX10013 biocryst.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BCX10013 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06100900 ↗ |